Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
1.290
-0.130 (-9.15%)
At close: Nov 20, 2026, 4:00 PM EST
1.310
+0.020 (1.55%)
After-hours: Nov 20, 2026, 7:41 PM EST
Quantum BioPharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
11.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marker Therapeutics | 2.31M |
| Seres Therapeutics | 2.13M |
| Pluri | 1.46M |
| Allarity Therapeutics | 350.00K |
| Fractyl Health | 3.00K |
QNTM News
- 3 days ago - 3 Quantum Computing ETFs with 47%+ Upside Potential, According to Analysts - TipRanks
- 7 days ago - Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up - GlobeNewsWire
- 9 days ago - Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares - GlobeNewsWire
- 15 days ago - Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold - GlobeNewsWire
- 23 days ago - 3 Quantum Computing ETFs with 30%+ Upside Potential, According to Analysts - TipRanks
- 6 weeks ago - Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial - TheFly
- 6 weeks ago - Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewsWire
- 7 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - GlobeNewsWire